Gilead pledges 400K AmBisome doses to fight visceral leishmaniasis in expanded WHO collab
21st May 2026 Uncategorised 0Gilead’s five-year contract with the WHO is centered on providing AmBisome to countries that make up 74% of the global visceral leishmaniasis burden, according to the company.
More: Gilead pledges 400K AmBisome doses to fight visceral leishmaniasis in expanded WHO collab
Source: fierce
